Our Ref: 52

JAN 2025



Freedom of Information Act Request

Under the Freedom of Information Act, I would like to request the following information:

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

18 patients

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

17 patients

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

17 patients

Plus 5 patients with relapsed DLBCL

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)

R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)

(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)

R-GemOX (rituximab, gemcitabine and oxaliplatin)

Axicabtagene ciloleucel

Tisagenlecleucel

Epcoritamab

Loncastuximab tesirine

Glofitamab

Any other SACT

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

R-GemOX (rituximab, gemcitabine and oxaliplatin)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Our Ref: 52

JAN 2025



Any other treatments

5 Patients

Q4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)?

2 Patients

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

1 Patient

CAR-T Therapy (E.g. Axicabtagene ciloleucel) Stem cell transplant or bone marrow transplant (autologous or allogeneic) Any other treatment

1 Patient